my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
18-09-2012: Mucosis B.V. announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.
Mr. Johnston joined Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy there, he developed and executed a regional partnership strategy concluding deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Mucosis Appoints Thomas Johnston to CEO
Mucosis B.V. announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.Mr. Johnston ... more
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath Platform In Humans
Mucosis B.V. announced Phase I clinical data providing proof-of-concept that Mimopath®-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.Mucosis, in conjunction with the Centre for Huma ... more
Mucosis Announces New Scientific Advisory Board
Mucosis B.V. announced that it has appointed professors Jiri Mestecky, M.D., Ph.D.; Willem van Eden, M.D., Ph.D.; and Peter J. Openshaw, M.B., B.S., Ph.D., F.Med.Sci., to its newly formed Scientific Advisory Board.Dr. Mestecky is with the Department of Microbiology and Medicine at the Unive ... more
Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidates are FluGEM™, an intranasal vaccine to prevent influenza, and PneuGEM™, a vaccine preventing diseases caused by pneumo ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
